Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication Early and one-year outcomes by Feiring, Andrew J. et al.
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Primary Stent-Supported Angioplasty
or Treatment of Below-Knee Critical
imb Ischemia and Severe Claudication
arly and One-Year Outcomes
ndrew J. Feiring, MD, FACC, FCSAI, Amy A. Wesolowski, RN, Susan Lade, RN
ilwaukee, Wisconsin
OBJECTIVES The objective of this study was an investigation of the safety and efficacy of primary
below-knee stent-supported angioplasty (BKSSA) for restoring straight inline arterial flow in
patients with critical limb ischemia (CLI) or lifestyle-limiting claudication (LLC).
BACKGROUND Surgical tibial bypass for CLI and severe LLC is associated with significant morbidity,
mortality, and graft failure, whereas percutaneous angioplasty is suboptimal.
METHODS Below-knee stent-supported angioplasty was attempted in 82 patients (92 limbs) with either
CLI (68%) or severe LLC (32%). Patients received daily aspirin, thienopyridine, and
glycoprotein IIb/IIIa agents during the procedure. One-month major adverse events (MAEs)
were defined as death, myocardial infarction, major unplanned amputation, need for surgical
revascularization, or major bleeding. Clinical success was defined as improved resting ankle
brachial index by 0.10, relief of resting pain, healing of ulceration or amputation, and
improvement of claudication.
RESULTS Mean age of patients was 74  17 years. In 86 limbs, straight inline flow was restored to at
least one tibial vessel. Technical success was 94% for de novo lesions and there were no
MAEs. Ankle brachial indexes increased for all groups (CLI  0.32  0.13 to 0.9  0.14
and LLC  0.65  0.09 to 0.95  0.12; p  0.0001, pre vs. post). Relief of rest pain and
healing of ulcerations and amputations were seen in 96% (47 of 49) of patients with CLI who
underwent successful intervention.
CONCLUSIONS Below-knee stent-supported angioplasty for CLI and LLC improves ankle brachial indexes
comparable to tibial bypass, heals amputations and ulcerations, relieves rest pain, and
improves ambulation. Because BKSSA is associated with minimal MAE, it may hold promise
as an alternative therapy for patients with CLI and LLC. (J Am Coll Cardiol 2004;44:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.0372307–14) © 2004 by the American College of Cardiology Foundation
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britical limb ischemia (CLI) and severe lifestyle-limiting
laudication (LLC) are often caused by flow-limiting ste-
osis or occlusion of a remaining below-knee artery. There
s no optimal remedy for these patients. The focus of
urgical therapy in patients with CLI is to either restore
traight inline arterial blood flow to at least one tibial vessel
r to amputate the limb when tissue loss or pain becomes
ntractable. Tibial bypass is underutilized in elderly and
igh-risk patients because of considerable procedural mor-
idity and mortality (1,2). Although bypass is usually
eserved for patients with rest pain or tissue loss, it is
nfrequently recommended for claudicants. In these pa-
ients, the risk-benefit ratio is often unfavorable because of
he attendant morbidity and mortality, as well as subsequent
isk of graft failure and the need to conserve saphenous veins
or future coronary bypass (2). Despite encouraging reports
3–6), the value of angioplasty for below-knee arterial CLI
nd LLC has not been widely accepted because of high
estenosis rates, abrupt vessel closure, thrombus formation,
erforation, embolization, and lack of demonstrable hemo-
ynamic improvement (2,7–10).
From the Columbia-St. Mary’s Medical Center, Milwaukee, Wisconsin.(
Manuscript received May 25, 2004; revised manuscript received August 26, 2004,
ccepted September 14, 2004.In patients undergoing coronary intervention, the use of
tents and antiplatelet antagonists has markedly reduced
cute complications and symptomatic restenosis compared
ith balloon angioplasty. Extrapolating from this experi-
nce, we postulated that patients with CLI and severe LLC
ith jeopardized single-vessel runoff would benefit from
imilar interventional techniques, including primary below-
nee stent-supported angioplasty (BKSSA) and aggressive
latelet blockade.
ETHODS
etween January 2000 and January 2003, patients with CLI
nd LLC were evaluated. Patients with CLI were usually
eferred because of lack of adequate vascular conduit or
urgical target, multiple co-morbidities, as a last attempt
efore amputation, or patient unwillingness to undergo
urgery. Critical limb ischemia was defined as: 1) persistent,
ecurring rest pain requiring analgesia and an ankle systolic
ressure 50 mm Hg and/or toe systolic pressure 30 mm
g; and/or 2) ulceration, gangrene, or nonhealing wounds
f the foot with ankle systolic pressure 50 mm Hg or toe
ystolic pressure 30 mm Hg (10). Patients with CLI are
y definition categorized as Rutherford category IV to VI
12). Lifestyle-limiting claudication was defined as Ruther-
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Treating Below-Knee Ischemia With Coronary Stents December 21, 2004:2307–14ord category II to III associated with jeopardized single-
essel runoff or complete trifurcation vessel occlusion. Be-
ore intervention, patients had rest and exercise ankle
rachial indexes (ABIs) recorded. Patients with noncom-
ressible tibial vessels were excluded from analysis unless the
ostintervention ABIs could be appropriately measured.
The decision to intervene was made at the time of
iagnostic angiography. Jeopardized runoff was defined as
ither complete trifurcation occlusion or a50% stenosis of
he remaining tibial vessel. Attempted revascularization was
riven by clinical necessity irrespective of the degree of
ollateralization. Because all patients were symptomatic, the
egree of collateralization was thought to be suboptimal.
atients with more proximal arterial inflow disease, in
ddition to below-knee disease, were included if upper-level
evascularization was successful. Patients with total occlu-
ions that could not be crossed with a wire were excluded
rom subsequent analysis. If both limbs were affected, the
xtremity with the most extensive tissue loss or the one that
as most symptomatic was addressed first.
Patients with histories suggestive of active coronary
schemia were evaluated and underwent appropriate surgical
r interventional myocardial revascularization before vascu-
ar intervention. Patients with renal insufficiency (creatinine
1.5 mg/dl) were adequately hydrated before and after the
rocedure. Starting in 2001, all patients with renal insuffi-
iency received pre- and post-procedural mucomyst at 600
g oral twice a day.
nterventional technique. The contralateral retrograde
pproach was used in all but three patients. Interventions
ere performed through a 5-F, 40 to 45 cm sheath (Rabbe,
ook, Bloomington, Indiana, or Pinnacle, Boston Scien-
ific, Maple Grove, Minnesota). If multilevel intervention
as contemplated, a 6-F sheath was used. The goal was to
aximize runoff and establish continuous inline flow in at
east one below-knee vessel to the ankle. The anterior or
osterior tibial arteries were preferred targets if available.
nterventions were performed with 135-cm low-profile
oronary balloon catheters. Total occlusions were crossed
ith 0.014-inch hydrophilic wires (Choice PT, Boston
cientific, or Shinobi, Cordis, Miami, Florida). Lesions
ere nominally predilated by one-half millimeter smaller
han the reference vessel. Four lesions were resistant to
igh-pressure balloon inflations and subsequently under-
Abbreviations and Acronyms
ABI  ankle brachial index
BKSSA  below-knee stent-supported angioplasty
CLI  critical limb ischemia
DES  drug-eluting stent
LLC  lifestyle-limiting claudication
MAE  major adverse events
MI  myocardial infarction
PTA  percutaneous transluminal angioplastyent successful Rotablation (Boston Scientific) or Cutting
a
calloon (Boston Scientific) angioplasty. A variety of
alloon-expandable and self-expanding coronary stents were
sed and deployed to obtain a10% residual. Angiographic
uccess was defined as dilation of all critical inflow lesions
ith a resulting residual stenosis of 20%. Technical
uccess was defined as a residual stenosis of 20% after
tent placement; Thrombolysis In Myocardial Infarction
TIMI) III antegrade flow; straight inline flow to the ankle
n at least one tibial vessel; and absence of distal emboliza-
ion, perforation, or need for unplanned corrective surgical
ntervention. All sheaths were either removed immediately
r within 1 h of the procedure. Vascular closure devices were
sed when appropriate.
ntiplatelet therapy. Before angiography all patients were
tarted on 81 mg aspirin or clopidogrel 75 mg daily. For
atients not taking clopidogrel, a loading dose of 450 mg
as given before the procedure. After arterial access, pa-
ients received unfractionated heparin at 60 /kg. Activated
lotting times were not monitored. After stent placement,
bciximab (Reopro, Eli Lilly, Indianapolis, Indiana) (0.125/
g/kg) followed by an infusion at 10 g/min for 12 h, or
btifibatide (Integrilin, Cor Therapeutics, South San Fran-
isco California) (180 U/kg bolus  2) followed by an 18-h
nfusion) were administered. If the 4-h platelet count fell
100,000, then the infusion was discontinued. Patients
ere discharged on indefinite aspirin and clopidogrel 75
g/day for six months or longer if financially feasible.
atients who were intolerant of clopidogrel received ticlo-
idine 250 mg twice daily.
linical end points. Clinical major adverse events (MAEs)
ere defined as death, stroke, myocardial infarction (MI),
enal failure, retroperitoneal bleed, unplanned tibial/pedal
ypass, major infection, compartment syndrome, acute renal
ailure, or need for procedure-related transfusion. Clinically
mportant renal failure was defined as an elevation of
ost-procedure creatinine 0.5 mg. Clinical success was
efined as continued relief of ischemic rest pain, reduction
n severity of claudication, healing of ulceration, and free-
igure 1. Distribution of patients based on success or failure of below-knee
tent-supported angioplasty. AMP-CLI  patients with critical limb
schemia (CLI) who subsequently underwent below-knee amputation after
ultiple failed interventions; PTA-LLC  percutaneous transluminal
ngioplasty for lifestyle-limiting claudication; TVR  target vessel revas-
ularization.
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December 21, 2004:2307–14 Treating Below-Knee Ischemia With Coronary Stentsom from unplanned surgical amputation or bypass surgery.
cheduled patient follow-up occurred at four weeks, six
onths, and one year. Rest and exercise ABIs were obtained
efore and four weeks after the procedure. Additional ABIs
ere obtained only if the patient’s clinical situation deteri-
rated. At six months patients were graded on a “clinical
mprovement scale” where 0 represented entry clinical sta-
us, 1, 2, and 3 represented minimal, moderately, and
arked improvements, and values 1, 2, and 3 repre-
ented mild, moderate, and marked worsening, respectively
13). Repeat angiography and target vessel revascularization
ere dictated by recurrent ulceration, rest pain, or worsen-
ng claudication.
tatistical analysis. Descriptive data are presented as the
ean value  SD. Mean data are presented as box-and-
hisker graphs, where the central box represents the values
rom the lower to upper quartile (25th to 75th percentile),
he middle line represents the median, and a line extends
rom the minimum to the maximum value, excluding
outside” values, which are displayed as separate points.
ignificant changes in ABI before and after intervention
ere evaluated by a paired Student t test with p  0.05
ndicating statistical significance. Because failure to cross a
otal occlusion had no influence on standard treatment,
hese patients were subsequently excluded from further
nalysis.
ESULTS
he clinical course of the 82 patients who underwent
ngiographic evaluation is described in Figure 1. In six
atients with CLI (7%), there was failure to cross the total
cclusion with a wire. No patient’s condition was worsened
y the attempted intervention. Four of these patients went
n to below-knee amputation and two had successful distal
ypass.
Seventy-six patients and 86 limbs underwent successful
ntervention. There was no significant difference between
he mean age of claudicants and those with CLI. Baseline
emographic data are presented in Table 1. Men outnum-
ered women by slightly 3:2. The mean age of patients
as 74.2  16.6 years with a range of 35 to 101 years. The
verage age of women patients was 4.5 years older than men.
emographic data are presented in Table 1. Before
KSSA, 12 patients (16%) underwent myocardial revascu-
arization, three underwent coronary artery bypass surgery,
nd nine underwent multivessel coronary angioplasty.
elow-knee stent-supported angioplasty was performed be-
ween 2 and 21 days after myocardial revascularization.
All infrageniculate lesions were either category III or IV
2). Technical success for all de novo lesions was 93% (86 of
2 limbs) and 94% (90 of 96) for all patients, including
hose with restenotic lesions. Once the wire crossed the
esion, technical success for restoring inline flow to the ankle
as 100% for the 86 limbs (76 patients). There were no
rocedural- or one-month–related deaths, MIs, amputa-
*
tions, unplanned vascular surgeries, or worsening of lower
imb ischemia. There was no evidence of embolization,
hrombosis, perforation, or arterial spasm. There were no
ajor access site complications or clinically relevant contrast
ephropathy. One patient developed uncomplicated IIb/
IIa-related thrombocytopenia, which delayed discharge by
hree days. Ninety-three percent of all patients were dis-
harged within 24 h of admission.
A negative residual was achieved for all stents placed. A
otal of 197 stents (mean  2.3  0.6 per patient) were
mplanted. Assortments of balloon expandable and self-
xpanding coronary stents were deployed (Table 2). Self-
xpanding stents were post-deployed at low pressure with a
oronary balloon size 0.5 mm greater than the reference
essel. There was no appreciable difference noted regarding
he deliverability or performance characteristics of the
tents. The Hepacoat (Cordis) stent was the later stent of
hoice because of its theoretical antithrombotic properties.
e preferred stents with closed-cell designs, unless side
ranch salvage was intended. Stent size ranged from 2.5 to
.0 mm. The median size stent for the distal popliteal and
ibioperoneal trunk was 4.0 mm, proximal anterior tibial/
able 1. Demographics—Patients Undergoing Intervention
n (%)
atients 76
imbs 86
Men 53 (62)
Women 33 (38)
ge (yrs) 74 15
Men 73 15
Women 76 13
AD 55 (72)
ABG 32 (42)
F 35% 28 (37)
iabetes 41 (54)
ypertension 65 (86)
r 1.5 mg % 29 (39)
moking 26 (34)
LI 49 (68)
laudication 37 (32)
ata are presented as the number (%) of patients.
CABG coronary artery bypass grafting; CAD coronary artery disease; CLI
ritical limb ischemia; Cr  creatinine; EF  ejection fraction.
able 2. Type and Distribution of Stents
Stent n (%)
rown* 18 (9)
x Velocity* 34 (17)
epacoat* 116 (59)
ypher* 3 (2)
adius† 12 (6)
ir† 4 (2)
xpress† 3 (2)
7‡ 7 (4)
otal no. of stents 197
Mean  SD per patient 2.3  0.6
edian diameter stent (mm) 3.5Cordis Corp.; †Boston Scientific Corp.; ‡Medtronic Corp. This table tabulates the
ype and distribution of coronary stents deployed.
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Treating Below-Knee Ischemia With Coronary Stents December 21, 2004:2307–14osterior tibial was 3.5 mm, and distal vessel or peroneal
rtery 2.5 to 3.0 mm. Concomitant superficial femoral and
r above-knee popliteal artery interventions were performed
n 27% of patients. Angiographic examples of critical limb
schemia and corresponding tibial interventions are shown
n Figures 2 and 3.
The preintervention mean ABI for the entire cohort was
.42  0.13, which improved to 0.90  0.14 at one month
p  0.0001) (Fig. 4). In patients with CLI, the mean ABI
ncreased from 0.32 0.13 to 0.9 0.14 (p 0.0001) (Fig.
). Those with claudication improved from 0.65  0.09 to
.95 0.12, (p 0.001) (Fig. 6). At six months, only three
atients felt that they had not improved, and no patients felt
hat they were worse off (Fig. 7).
Clinical outcomes during the first year after BKSSA are
hown in Table 3. During the first month there were no
AE. All patients completed the six-month and one-year
linical follow-up. Planned amputations occurred in eight
atients. Six patients underwent toe amputations and two
ad transmetatarsal amputations. All amputations healed.
wo patients with ulcerations initially healed and then
ecurred secondary to in-stent restenosis. Repeat angio-
lasty was unsuccessful and they ultimately underwent
cheduled below-knee amputation. All patients with resting
schemic pain improved. These improvements were sus-
ained over the first year. The one-year limb salvage rate for
LI was 47 of 49 limbs (96%) for those patients with initial
echnical success. When the data were expressed on an
igure 2. (A) Sixty-year-old diabetic woman. Note the deep, broad-based
rachial index was 0.42 with a toe pressure of 25 mm Hg. Before vascular
isease. (B) Three months after primary stent-supported intervention, aspir
aintained for three years. (C) Pre-intervention angiogram demonstratin
ubtotal occlusion (solid arrows), of the anterior tibial artery. (D) Post
epacoat (Cordis) stents. One-month resting ankle brachial index normantention-to-treat basis, the one-year limb salvage rate for Dll patients undergoing angiographic evaluation was 87%.
uring the first year there were no deaths, MIs, or strokes.
etween the 6th and 12th months, four patients underwent
epeat angiographic evaluation. Two patients developed
n-stent restenosis and two demonstrated progressive super-
cial femoral artery disease. All patients underwent success-
ul percutaneous therapy. Contemporaneous angiography
emonstrated no evidence of stent crush.
ISCUSSION
his study underscores the following unique observations:
Below-knee stent-support angioplasty is associated with a
igh rate of angiographic success, minimal MAE, and short
ospital stay, even in the elderly with multiple co-
orbidities.
Stent-supported below-knee percutaneous transluminal
ngioplasty (PTA) results in normalization of the one-
onth postintervention ABIs comparable to that seen after
uccessful surgical tibial bypass (13).
During the first year after successful stenting, 95% of
atients (82 of 86) demonstrated tissue healing, relief of
esting ischemic pain, and improvement in claudication.
Using aspirin, thienopyridine, and glycoprotein IIb/IIIa
nhibitor, we observed no evidence of abrupt stent occlusion
r distal embolization.
imitations of current therapy for CLI and below-knee
LC. Patients with CLI have a dismal clinical course.
ealing foot ulcer. Despite five months of conservative therapy, the ankle
ention she underwent coronary bypass for left main three-vessel coronary
d clopidogrel, the ulceration demonstrates complete healing that has been
plete occlusion of the posterior tibial and peroneal arteries and a long
vention angiogram after placement of two balloon-expandable coronary
to 0.98.nonh
interv
in, an
g comuring the first year of diagnosis, mortality is 20% to 30%,
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December 21, 2004:2307–14 Treating Below-Knee Ischemia With Coronary Stentsnd an equivalent number undergo amputations or suffer
ersistent pain (2). The surgical options of either amputa-
ion or tibial bypass have changed little since 1966 (14).
urgical complications include death (1.3% to 6%), MI
1.9% to 3.4%), wound infections (10% to 30%), leg edema
50% to 100%), and early graft failure rates (6% to 49%)
equiring repeat surgery (2,15). When the conduit used is
olytetrafluoroethylene, the five-year patency rates are as
igure 3. (A) Pre-intervention angiogram in a 78-year-old man with
ifestyle-limiting claudication and resting ankle brachial index (ABI) of
.41. Note the total occlusion of the distal popliteal artery (A) and absence
f any named tibial vessels. (B) Postintervention angiogram with a 4.0 
2-mm stent placement in the popliteal artery and a 3.5  32-mm stent
laced in overlapping fashion extending into the posterior tibial artery.
ne-month ABIs normalized to 1.03 and claudication was relieved.ow as 33% (2). Ultimately, bypass surgery can only be cffered to a minority of patients because of inadequate
onduit, poor runoff, advanced age, and cardiac and/or other
o-morbidities. Thus, definitive treatment is often withheld
rom those patients who would most benefit.
Angioplasty for CLI was reported nearly 40 years ago
16). Initial complications were high and success low,
econdary to bulky catheters and guide wires, perforation,
hrombosis, and vascular trauma related to antegrade punc-
ure (2,5,6). Despite recent technologic advances, Hanna et
l. (6) reported a 21% procedural complication rate, includ-
ng embolization and thrombosis in patients with CLI
ndergoing balloon angioplasty, whereas Dorros et al. (3)
emonstrated that PTA of below-knee arteries could be
erformed with relative safety and with satisfactory results.
he prevailing surgical perspective regarding tibial angio-
lasty was articulated by Dormandy and Rutherford (2),
ho stated, “below-knee PTA should be considered in
atients with limb-threatening ischemia without good sur-
ical options or lack of conduit” and that “stents have not
een adapted to use in the infrapopliteal vasculature.” Thus,
he goal of this study was to address these perceived
imitations using contemporary coronary interventional
echniques.
enefits of BKSSA for CLI. This is the first study to
emonstrate the clinical and hemodynamic efficacy and
afety of primary stent support below-knee angioplasty for
LI and severe LLC. Previously, only surgical bypass has
een shown to improve hemodynamics measured by ABIs
13). In this study, the magnitude of ABI improvement was
quivalent to that obtained with bypass surgery, yet it was
ccomplished with a fraction of surgery’s morbidity and
ortality. During the first year, improvement in distal
erfusion pressure paralleled relief of resting pain, resolution
f all but two ulcerations, and healing of all elective
mputations. Despite the advanced age of our patients (1 of
80 years), BBSSKA could be accomplished with mini-
al procedural risks. Most importantly, there was no
igure 4. Box and whisker plot for the entire cohort, depicting the resting
nkle brachial index (ABI) before (pre) and after (post) intervention. *p 
.0001 for improvement in ABI from baseline.linical penalty for attempted endovascular intervention. If
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Treating Below-Knee Ischemia With Coronary Stents December 21, 2004:2307–14eeded, repeat PTA could be attempted, and BKSSA did
ot appear to preclude future surgical options.
During the first year there were no deaths or MIs and
nly two leg amputations. This is in contrast to a 30% death
nd amputation rate expected in traditionally treated CLI
atients (17). The improved outcomes may have been
econdary to the confluence of early coronary revasculariza-
ion, avoidance of amputations and surgery, aggressive
latelet inhibition, and universal use of lipid-lowering
gents.
tent-supported below-knee angioplasty for LLC. Clau-
ication and CLI represent a continuum of the same
therosclerotic process. The expected rate of progression
rom claudication to amputation is reported as 1% per year,
lthough more than 20% of claudicants will develop inca-
acitating LLC, seriously restricting the quality of life and
ndependence of older patients (1,2,18,19). Surgical options
or patients with severe LLC are limited, especially if venous
onduit must be conserved for future coronary artery bypass.
owever, most importantly, there is the prospect that an
nsuccessful tibial bypass may convert a “stable claudicant”
nto a limb salvage patient. For this same reason the use of
TA for below-knee claudicants has been restricted. This
pproach is supported by the Transatlantic Inter-Society
onsensus document, which states, “infrapopliteal vessels
re usually not treated unless there is critical acute or chronic
imb ischemia” (2).
This is the first study to demonstrate that BKSSA can
ormalize ABI hemodynamics in patients with severe LLC.
s in patients with CLI, improvement was accomplished
ith a minimum of MAE, and no patient was clinically
orse off one year after intervention. Below-knee stent-
upported angioplasty afforded many older patients the
bility to improve their quality of life with minimal risk.
xtrapolation of these data to patients with less severe
laudication should be done cautiously. Our patients are a
nique subset who have jeopardized single-vessel runoff and
igure 5. Box and whisker plot for patients with critical limb ischemia
CLI), depicting resting ankle brachial index (ABI) before (pre) and after
post) intervention. *p  0.0001 for improvement in ABI from baseline.hus should be considered to be in a pre-CLI stage.
c
sechnical considerations. The endovascular methodology
as standardized to minimize suboptimal interventional
echnique. We routinely used a retrograde contralateral
pproach, 6-F sheath size, sub 3.5-F balloons, 0.014-inch
ires, high-pressure stent deployment, reduction of all
tenosis 20%, maximization of distal runoff to ankle, and
riple platelet inhibition. Applying this algorithm there were
AE. Using contralateral retrograde arterial access, we
oticed little reduction in wire responsiveness, although an
ntegrade approach may have improved success for recana-
izing total occlusions. The application of coronary stents to
elow-knee intervention is untested. However, both coro-
ary and infragenoual arteries are medium-sized muscular
rteries of similar dimensions. The median stent diameter
eployed was 3.5 mm (range 2.5 to 5.0 mm), which is
dentical to the average-sized coronary stent. Because stents
mprove postintervention luminal cross-sectional area, pre-
ent early recoil and negative remodeling, and tack up
igure 6. Box and whisker plot for patients with severe lifestyle-limiting
laudication and jeopardized single-vessel runoff, depicting resting ankle
rachial index (ABI) before (pre) and after (post) intervention. *p 0.0001
or improvement in ABI from baseline.
igure 7. Qualitative improvement in baseline symptoms for the entire
ohort. *p  0.0001 for improvement from baseline. There were no
ignificant changes between one month and six months.
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December 21, 2004:2307–14 Treating Below-Knee Ischemia With Coronary Stentsntimal flaps and dissections, there is little reason to suspect
hat this approach would not be effective for below-knee
rterial interventions.
tudy limitations. This was a single-center, single-
perator, consecutive patient trial. Ankle brachial indexes
ere obtained before intervention to document hemody-
amic impairment and at one month after intervention to
easure improvement. Subsequent ABIs were obtained
hen there was a question of worsening clinical status.
herefore, one-year stent patency rate and ABI data are not
eported. Nevertheless, the fate of patients who underwent
KSSA can be compared to the known natural history of
atients with CLI. Patients undergoing successful interven-
ion had a 96% freedom rate from major amputation
ompared with historic one-year amputation rates of 30%
2,15). Furthermore, the need for target vessel revascular-
zation was only 8% compared with surgical revision rates as
igh as 49% (2). Published surgical data suggest that
ong-term patency of tibial bypass grafts for CLI may not be
mperative as long as the duration of blood flow is enough
o effect complete tissue healing (20). Therefore, although
erial ABIs or angiographic follow-up would have been
deal, the fact that nearly all patients demonstrated sustained
linical improvement suggests that BKSSA may be a prom-
sing alternative to tibial bypass surgery.
The therapeutic goal for patients with LLC is to increase
unctionality, which can only be achieved by sustained
emodynamic improvement. Because all patients had jeop-
rdized single-vessel runoff, occlusion of the sole remaining
essel would have resulted in worsening symptoms or CLI.
uring the first year, all patients with LLC improved and
o patient regressed to baseline, suggesting continuous stent
atency. Consequently, even without one-year ABIs, our
ata suggest that BKSSA for LCC has few of the limita-
ions of tibial bypass surgery and provides an equivalent
arly benefit.
able 3. Clinical Status
30-Day Fo
CLI (%)
rocedure to discharge (days) 1.4 0.4
linical status, n (%)
Improved 47 (96)
Unchanged 2* (4)
Worsened 0
Procedure-related death 0
Non-procedure–related death 0
bility to cross lesion (%) 49/55 (89)
echnical success (%) 49/49 (100)
epeat tibial intervention 0
lanned minor amputation 6
lanned major amputation 2†
nplanned major amputation —
ealed amputation —
ata are presented as the number (%) of patients. *Represents patients unimproved af
aseline; §restenosis after initial successful intervention; subsequent amputation afte
CLI  critical limb ischemia; LLC  lifestyle-limiting claudication.The possibility of stent crush cannot be excluded, al- phough those returning for repeat intervention revealed no
vidence of stent deformation. Furthermore, because all
atients had jeopardized single-vessel runoff, mechanical
ompromise of their remaining tibial vessel would readily
anifest itself as failure to heal ulceration, recurrence of rest
ain, or worsening claudication. With the exception of the
istal popliteal artery and anterior and posterior tibial
rteries, all crural vessels are circumferentially protected by
he anterior and posterior muscle compartments. When
tenting these areas, we favor the use of self-expanding
oronary nitinol stents (i.e., Radius, Boston Scientific).
The expense of implanting multiple stents can be con-
iderable, although potential cost savings may be realized by
horter hospitalizations and reduction in surgeries, amputa-
ion, and extended rehabilitation. Moreover, with the ad-
ent of drug-eluting stents (DES), the price of bare-metal
tents continues to decline. Our preliminary data suggest
hat clinically significant in-stent restenosis is 10%. How-
ver, because the need for repeat angiography was driven by
orsening symptoms, we have no data on binary restenosis
ates. It is hoped that issues of acute gain and late loss will
e addressed by industry-supported trials. Although it is
remature to speculate how DES will fit into this treatment
aradigm, it is reasonable to postulate that DES should
nhibit crural neointimal hyperplasia similar to coronary
essels, and thereby reduce restenosis in high-risk patients
ith diabetes, small-diameter vessels, and long lesions (21).
o date we have treated 14 patients with high-risk variables
or restenosis (not included in this analysis) with Cypher
Cordis) DES without adverse events.
Although we encountered no evidence of stent thrombo-
es, the implication of abrupt stent occlusion is of para-
ount concern in patients with single-vessel runoff. For this
eason we employed the same effective pharmacologic algo-
ithm used to prevent abrupt closure after coronary stenting.
his is the first study to report on the use of multilevel
Up 1-Year Follow-Up
LLC (%) CLI (%) LLC (%)
0.9  0.3 — —
37 (100) 45 37
0 4‡ 0
0 0 0
0 0 0
0 0 0
37/37 (100) 2/2 (100) 2/2 (100)
37/37 (100) 2/2 (100) 100 (100)
0 2§ 2§
0 — —
0 2 —
0 — —
0 8/8¶ —
ervention; †transmetatarsal amputations; ‡unchanged compared with preintervention
nd restenosis; ¶healed planned amputation at one year.llow-
ter intlatelet blockade for infragenoual endovascular revascular-
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n studies showing a significant reduction in stroke death
nd MI in patients with vascular disease (22), as well as
xtensive coronary interventional data demonstrating reduc-
ion in MAE after coronary stenting (23). Finally, IIb/IIIa
gents were empirically added because of the well-known
ffect of these agents for reducing the incidence of early
hrombotic complications after angioplasty (24). Thus, al-
hough the efficacy of these agents has been well established
or coronary intervention, there are no specific data that
upport their effectiveness in lower extremity intervention.
he effectiveness of these agents, either alone or in combi-
ation, will need to be evaluated in controlled trials.
onclusions. This study demonstrates the early and mid-
erm safety and efficacy of BKSSA both for CLI and severe
LC. Percutaneous intervention with primary stent-
upported intervention offers immediate and consistent
ndoluminal reconstruction with near normalization of
BIs. These improvements in hemodynamics were associ-
ted with healing of ulceration, elective amputations, and
bility to ambulate. Because primary stent-supported endo-
ascular therapy is effective, has few adverse effects, and does
ot preclude future tibial bypass surgery, it may be consid-
red as an option for patients with CLI and severe LLC
ith jeopardized single-vessel runoff. The relative benefits
f adjunctive antiplatelet therapy, DES, and preintervention
oronary artery revascularization need further study.
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